Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
|Articles|March 23, 2020
PsychPearls: Battling Loneliness During the COVID-19 Pandemic
Author(s)Joshua C. Morganstein, MD
What can psychiatrists do to help their patients cope with self-quarantine and isolation practices? More in this podcast.
Advertisement
We have invited Dr Joshua Morganstein, Chair of the
What can psychiatrists do to help their patients cope with self-quarantine and isolation practices?
Have more COVID concerns and clinical tips? Email us at
Advertisement
Related to this article
Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
2
Interventional Options for TRD: ECT, TMS, and Esketamine
3
Vortioxetine's Effect on Cognitive Function in Older Adults With Major Depressive Disorder
4
Defining Treatment-Resistant Depression In Adults
5